Bioinformatics and Computational Biology Core

项目摘要 阿尔茨海默病（AD）影响当今全世界约4000万人，并且是阿尔茨海默病的最常见形式。 痴呆症主要发生在老年人身上。AD是一种高度异质性的疾病， 包括多年来的渐进性记忆和认知领域退化，最终导致死亡 确诊后3-9年。在过去的几十年里，许多假说被提出作为潜在的 AD的发病机制涉及多种生物学过程，如蛋白质发病机制、线粒体 异常、病毒感染和其他神经胶质细胞介导的免疫应答。然而，疾病的病因 其发病机制尚不清楚，目前尚无有效的治疗方法。在过去 多年来，AD研究界一直在努力寻找潜在的药物靶点。 其中，AMP AD在基于来自以下方面的证据产生药物靶点候选物方面处于领先地位： 多项研究。随着这些项目积累的大量数据，需要进行更深入的分析 再加上广泛的下游药物开发技术，以完善目标候选名单， 确定潜在的新靶点以及可能的药物。ADDD项目旨在建立整个工作流程 并雄心勃勃地发现治疗AD的新药。作为我们ADDD项目整体工作的一部分， 生物信息学和计算生物学核心（BCB核心）将在该团队中发挥关键作用。巴西央行 核心将发挥三大作用。首先，BCB核心将引领基础设施的发展， 管理、处理、分析、可视化和共享来自该项目的大型AD数据集以及公共数据集 源其次，BCB核心将开发和建立先进和新颖的数据集成方法， 预测和优先考虑可药物化的目标，以及潜在的再利用候选药物AD。最后但 同样重要的是，BCB核心将为整个项目提供生物信息学数据处理和分析支持 通过密切合作和协调，涵盖AD药物靶标识别和测试的生命周期 与ADDD中心的其他核心。

Project Summary Alzheimer’s disease (AD) affects about 40 million people worldwide today, and is the most common form of dementia found predominantly in elderly people. AD is a highly heterogeneous disease with major symptoms including progressive memory and cognitive domain deterioration over years, which eventually leads to death about 3-9 years after diagnosis. During the past few decades, many hypotheses have been proposed as potential mechanisms for AD, which involve multiple biological processes such as proteopathogenesis, mitochondrial abnormality, viral infection, and other glia cell-mediated immunological response. However, the disease etiology and mechanism still remain unclear, and currently, there is still no curative treatment for AD. During the past years, multiple endeavors have been taken by the AD research community to identify potential drug targets. Among them, AMP ADis leading the charge of generating drug target candidates based on evidences from multiple studies. With the large amount of data accumulated from these projects, it calls for deeper analysis coupled with extensive downstream drug development technologies to refine the target candidate lists and also identify potential new targets as well as possible drugs. The ADDD project aims to establish the entire workflow for this process and ambitiously discover new drugs for AD. As part of the overall effort of the our ADDD project, the Bioinformatics and Computational Biology Core (BCB Core) will play a critical role in this team. The BCB Core will play three major roles. First, the BCB Core will lead the development of the infrastructure enabling curation, processing, analysis, visualization, and sharing of large AD datasets from this project as well as public sources. Secondly, the BCB Core will develop and establish advanced and novel data integration methods for predicting and prioritizing druggable targets as well as potential repurposing drug candidates for AD. Last but not the least, the BCB Core will provide bioinformatics data processing and analysis support for the entire project covering the lifecycle of the AD drug target identification and testing by closely collaborating and coordinating with other cores for the ADDD center.